Metoject Subcutaneous 12.5 mg

METOJECT SUBCUTANEOUS 12.5 MG is a solution containing methotrexate sodium, used for various medical conditions. This subcutaneous injection is manufactured by Medexus Pharmaceuticals Inc. in Canada.

METOJECT SUBCUTANEOUS 12.5 MG is primarily used for conditions that require methotrexate sodium. It is often prescribed for certain types of cancer, rheumatoid arthritis, and psoriasis. The solution is administered subcutaneously, allowing for targeted delivery. Patients and healthcare providers often seek information on what is methotrexate used for and how it works in these conditions.

Common effects of METOJECT SUBCUTANEOUS 12.5 MG may include redness or swelling at the injection site. Some users might experience nausea, fatigue, or mild gastrointestinal discomfort. These effects can vary depending on individual health conditions and other factors.

METOJECT SUBCUTANEOUS 12.5 MG should be handled with care. It is important to follow the administration guidelines provided by a healthcare professional. Store the solution as directed to maintain its efficacy. Always consult a healthcare provider before starting or stopping any medication.

METOJECT SUBCUTANEOUS 12.5 MG may interact with certain medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and other immunosuppressants. Alcohol consumption should be avoided as it can exacerbate side effects. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.